NCT06275620View on ClinicalTrials.gov

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2029

Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIOLOGICAL

AGTC-501 (high dose and standard corticosteroid regimen)

Adeno-associated virus vector expressing a human RPGR gene

BIOLOGICAL

AGTC-501 (low dose and standard corticosteroid regimen)

Adeno-associated virus vector expressing a human RPGR gene

BIOLOGICAL

AGTC-501 (high dose and modified corticosteroid regimen)

Adeno-associated virus vector expressing a human RPGR gene

Trial Locations (7)

32209

University of Florida, Jacksonville

33136

Bascom Palmer Eye Institute, Miami

44195

Cleveland Clinic, Cleveland

45242

Cincinnati Eye Institute, Cincinnati

75231

Retina Foundation of the Southwest, Dallas

97239

Casey Eye Institute, Portland

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY

NCT06275620 - A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | Biotech Hunter | Biotech Hunter